Abstract:OBJECTIVE To evaluate the dosing regimens of levofloxacin. METHODS The drug concentrations in serum and urine were assayed by HPLC method and the pharmacokinetic parameters were calculated after intravenous infusion of a single dose of 200 mg, 300 mg and 500 mg levofloxacin to healthy volunteers. The in vitro activity MIC of levofloxacin against 823 clinical isolates were determined and compared with other antimicrobial agents. Based on the above results, the PK/PD parameters C(max)/MIC and AUC/MIC were calculated and the dosing regimens of levofloxacin were proposed for infections caused by different pathogens. RESULTS The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg. The in vitro pharmacodynamic study showed that levofloxacin was highly active against Hemolytic streptococcus and Moraxella catarrhalis. It was active against Streptococcus pneumoniae (including penicillin nonsusceptible strains), Hemophilus influenzae, methicillin-sensitive Staphylococcus aureus (MSSA), Klebsiella pneumoniae and Stenotrophomonas maltophilia. Levofloxacin also had good activity against Pseudomonas aeruginosa and K.pneumoniae. However, most of isolates of enterococcal spp. were resistant to levofloxacin. Above 50% of Escherichia coli isolates were resistant to levofloxacin. Based on the results of PK/PD parameters, the adequate dosing regimens of levofloxacin should be once daily 200 mg once daily of levofloxacin was expected to be effective for the treatment of infections caused by M. catarrhalis. The regimen of 300 mg once daily could be effective for the treatment of infections caused by Hemolytic streptococcus. 500 mg once daily of levofloxacin was expected to be effective for the treatment of respiratory tract infections caused by S. pneumoniae or H. influenzae. For treatment of respiratory tract infections and urinary tract infections caused by levofloxacin-susceptible organisms including K. pneumoniae, E. coli, P. aeruginosa, and S.maltophilia, 500 mg once daily of levofloxacin was needed to obtain good clinical efficacy. But PK/PD parameters predicted that 500 mg daily of levofloxacin was not effective for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci. CONCLUSION The proposed dosing regimens of levofloxacin based on PK/PD concepts are expected to provide good efficacy in clinical practice.

Dosing regimen selection for pazufloxacin tablet in clinical trial based on its pharmacokinetic/pharmacodynamic analysis

Study on the optimization of pazufloxacin in clinical application based on PK/PD theory

Influence of Pazufloxacin Mesilate on Pharmacokinetics of Aminophylline in Rabbits

[Study of Pharmacokinetics/pharmacodynamics of Levofloxacin].

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy C hinese volunteers and dosing regimen optimization

Pharmacokinetics of pazufloxacin single dose intravenous in healthy volunteers

Pharmacokinetic/pharmacodynamic study of sparfloxacin

Pharmacokinetics of Pazufloxacin Mesilate Sodium Chloride in healthy Chinese volunteers after intravenous injection

Pharmacokinetics And Pharmacodynamics Of Levofloxacin Injection In Healthy Chinese Volunteers And Dosing Regimen Optimization

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

Dose Findings of Antofloxacin Hydrochloride for Treating Bacterial Infections in an Early Clinical Trial Using PK-PD Parameters in Healthy Volunteers

Pharmacokinetics of pazufloxacin mesilate sodium chloride for injection

Pharmacokinetics study of pazufloxacin mesylate in single dose in Chinese healthy volunteers

PK/PD of pazufloxacin against pathogen from community acquired infection

A clinical randomized controlled trial of pazufloxacin injection in treatment of bacterial infection in 111 patients

Pharmacokinetics of Pazufloxacin Mesilate in Chinese Healthy Volunteers

Pharmacokinetics of Pazufloxacin Injection in Healthy Volunteers

A Randomized, Controlled, Multicenter Clinical Trial To Evaluate The Efficacy And Safety Of Oral Sitafloxacin Versus Moxifloxacin In Adult Patients With Community-Acquired Pneumonia

Lefamulin Dosing Optimization Using Population Pharmacokinetic and Pharmacokinetic/pharmacodynamic Assessment in Chinese Patients with Community-Acquired Bacterial Pneumonia

Concentration-resistance relationship and PK/PD evaluation of danofloxacin against emergence of resistant Pasteurella multocida in an in vitro dynamic model

Sitafloxacin Pharmacokinetics/pharmacodynamics Against Multidrug-Resistant Bacteria in a Dynamic Urinary Tract Infection in Vitro Model.